Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07137910
PHASE2

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Sponsor: Ausper Biopharma Co., Ltd.

View on ClinicalTrials.gov

Summary

This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.

Official title: An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-09-04

Completion Date

2027-06-01

Last Updated

2026-08-05

Healthy Volunteers

No

Interventions

DRUG

AHB-137

AHB-137 will be injected

DRUG

NA therapy

NA will be usede.

Locations (12)

AusperBio Investigational Site

Beijing, Beijing Municipality, China

AusperBio Investigational Site

Jilin City, Changchun, China

AusperBio Investigational Site

Chongqing, Chongqing Municipality, China

AusperBio Investigational Site

Chongqing, Chongqing Municipality, China

AusperBio Investigational Site

Xiamen, Fujian, China

AusperBio Investigational Site

Guangzhou, Guangdong, China

AusperBio Investigational Site

Shenzhen, Guangdong, China

AusperBio Investigational Site

Nanning, Guangxi, China

AusperBio Investigational Site

Zhengzhou, Henan, China

AusperBio Investigational Site

Changzhou, Jiangsu, China

AusperBio Investigational Site

Chengdu, Sichuan, China

AusperBio Investigational Site

Hangzhou, Zhejiang, China